



Shareholder Update

ASX: RHT

09 June 2015

Disclaimer

This presentation has been prepared by Resonance Health and may contain forward-looking statements that are based on the board and management's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described.

Forward looking statements contained in this presentation may include statements about future financial and operating results, status of regulatory submissions, possible or assumed future growth opportunities and risks and uncertainties that could affect Resonance Health's products and services.

These statements are not guarantees of future performance, involve certain risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may not prove accurate.

Therefore, actual outcomes and results may differ materially from what is expressed herein. In any forward looking statement in which Resonance Health expresses an expectation or belief as to future results, such expectation or belief is expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will result or be achieved or accomplished.

You are urged to view all forward-looking statements contained herein with caution.

Company Snapshot

Financial Profile

ASX Code:	RHT
Share Price:	4.5cents
Market Capitalisation	\$18.07m
Cash 31 st March 2015	\$2.9m

No Debt

Top 20 Shareholders – 45%

Share Price History



Experienced Board and Management team, established relationships with pharmaceutical companies, expertise to commercialise development pipeline.

Liver Fibrosis Market

Market Information:


- Large addressable market for a non-invasive liver fibrosis diagnostic
- Liver fibrosis (scarring) is caused by:
 - Fatty liver disease
 - 1/3 of American adults have fatty liver
 - prevalence of fatty liver disease in China has approx doubled in the past decade
 - Viral hepatitis (affecting 170m worldwide, 2.7m US, 200k+ UK)
 - Iron overload and excess alcohol consumption
- Liver fibrosis can progress to liver cirrhosis and is a significant predictor of liver cancer

Liver Fibrosis Market

Clinical Need:

- Early diagnosis of fibrosis and effective management can significantly improve patient outcomes
- Pharmaceutical companies and clinicians need access to an accurate non-invasive diagnostic tool to assess liver fibrosis
- Pharma companies working in this area include:
 - Intercept
 - Galmed
 - Gilead
 - Shire
 - Immuron
 - Conatus

Company Product Overview



FerriScan® & HepaFat-Scan®

FerriScan:

- Non-invasive Liver Iron Concentration (LIC) measurement
- FDA, TGA and CE mark clearance
- Accepted as gold standard LIC measurement
- Profitable operation
- Continued interest from pharmaceutical companies

HepaFat-Scan:

- Non-invasive liver fat measurement
- FDA, TGA and CE mark clearance
- Winner of WA Innovator of the Year
- Collaboration with KOLs in the clinical community to participate in a number of studies which will generate data to enhance the acceptance and uptake of HepaFat-Scan
- Agreement has been reached to commence the first study:
12 – 18 month US study in a paediatric patient cohort with NAFLD

Contact

- Adrian Bowers (CFO)

AdrianB@resonancehealth.com

- Sander Bangma (GM)

SanderB@resonancehealth.com

- P: +61 (0)8 9286 5300

E: info@resonancehealth.com

W: www.resonancehealth.com